EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, 2cureX AB's enterprise value is kr-11.91 Mil.
2cureX AB's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was kr0.25 Mil. Therefore, 2cureX AB's EV-to-Revenue for today is -47.82.
The historical rank and industry rank for 2cureX AB's EV-to-Revenue or its related term are showing as below:
OSTO:2CUREX'
s EV-to-Revenue Range Over the Past 10 Years
Min: -52.21 Med: 2432.44 Max: 5504.4
Current: -47.82
During the past 8 years, the highest EV-to-Revenue of 2cureX AB was 5504.40. The lowest was -52.21. And the median was 2432.44.
OSTO:2CUREX's EV-to-Revenue is ranked better than 98.75% of 1042
companies
in the Biotechnology industry
Industry Median: 8.155
vs OSTO:2CUREX: -47.82
As of today (2024-05-21), 2cureX AB's stock price is kr0.352.
2cureX AB's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was kr0.02. Therefore, 2cureX AB's PS Ratio for today is 23.47.
2cureX AB EV-to-Revenue Historical Data
The historical data trend for 2cureX AB's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of 2cureX AB's EV-to-Revenue
For the Biotechnology subindustry, 2cureX AB's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
2cureX AB's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 2cureX AB's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where 2cureX AB's EV-to-Revenue falls into.
2cureX AB's current Enterprise Value is kr-11.91 Mil.
2cureX AB's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.25 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2cureX AB's share price for today is kr0.352.
2cureX AB's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2cureX AB EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of 2cureX AB's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
2cureX AB is a biotech company. The company is engaged in improving treatment efficiency, mainly for cancer patients. It is involved in developing a product, namely IndiTreat, which is a technology for the treatment of colorectal, ovarian, and pancreatic cancers. The company's sub-products include IndiTreat Test, IndiTreat clinical programs, and IndiTreat Therapy Design.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OSTO:2CUREX has been successfully added to your 